Undisclosed celiac disease therapeutic / Mozart Therap - LARVOL DELTA

Preclinical characterization of MTX-101: a novel bispecific CD8 Treg modulator that restores CD8 Treg functions to suppress pathogenic T cells in autoimmune diseases. (PubMed, Front Immunol) - "MTX-101 reduced antigen induced epithelial cell death in disease affected tissues, including in tissue biopsies from individuals with autoimmune disease (i.e., celiac disease, Crohn's disease). MTX-101 selectively bound CD8 Treg without unwanted immune cell activation or increase of pro-inflammatory serum cytokines and exhibited an antibody-like half-life in pharmacokinetic and exploratory tolerability studies performed using IL-15 transgenic humanized mice with engrafted human lymphocytes, including CD8 Treg at physiologic ratios. Collectively, these data support the development of MTX-101 for the treatment of autoimmune diseases."

Journal • Preclinical • Celiac Disease • Crohn's disease • Gastroenterology • Graft versus Host Disease • Immunology • Inflammation • Inflammatory Bowel Disease • CD4 • CD8 • IL15 • KIR2DL1 • KIR2DL3

A NOVEL BISPECIFIC CD8 TREG MODULATOR TARGETING CYTOLYTIC CD8 REGULATORY T CELLS REDUCES PATHOGENIC CD4 T CELLS AND INFLAMMATION IN TRANSLATIONAL MODELS OF INTESTINAL AUTOIMMUNE AND INFLAMMATORY DISEASE (DDW 2023) - "Our results indicate that bispecific CD8 Treg modulators activate CD8 Tregs in vitro, in vivo, and in human tissue resulting in decreased inflammation and amelioration of disease. The data suggest that this network can be targeted by immune-modulating biologics to suppress pathogenic T cells, to reduce disease severity & delay onset, and to potentially mitigate severity & frequency of flares in patients with Celiac disease and IBD."

Acute Graft versus Host Disease • Celiac Disease • Crohn's disease • Gastroenterology • Graft versus Host Disease • Immune Modulation • Immunology • Inflammation • Inflammatory Bowel Disease • CD4 • CD8